J 2021

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

RIAD, Abanoub, Andrea POKORNÁ, Sameh ATTIA, Jitka KLUGAROVÁ, Michal KOŠČÍK et. al.

Basic information

Original name

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

Authors

RIAD, Abanoub (818 Egypt, guarantor, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Sameh ATTIA, Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Michal KOŠČÍK (203 Czech Republic, belonging to the institution) and Miloslav KLUGAR (203 Czech Republic, belonging to the institution)

Edition

Journal of Clinical Medicine, Basel, MDPI, 2021, 2077-0383

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.964

RIV identification code

RIV/00216224:14110/21:00121325

Organization unit

Faculty of Medicine

UT WoS

000638607800001

Keywords in English

adverse effects; BNT162 vaccine; cross-sectional studies; COVID-19; Czech Republic; drug-related side effects and adverse reactions; health personnel; mass vaccination; prevalence

Tags

International impact, Reviewed
Změněno: 17/5/2022 08:58, Mgr. Tereza Miškechová

Abstract

V originále

Background: COVID-19 vaccine side effects have a fundamental role in public confidence in the vaccine and its uptake process. Thus far, the evidence on vaccine safety has exclusively been obtained from the manufacturer-sponsored studies; therefore, this study was designed to provide independent evidence on Pfizer–BioNTech COVID-19 vaccine side effects. Methods: A cross-sectional survey-based study was carried out between January and February 2021 to collect data on the side effects following the COVID-19 vaccine among healthcare workers in the Czech Republic. The study used a validated questionnaire with twenty-eight multiple-choice items covering the participants’ demographic data, medical anamneses, COVID-19-related anamneses, general, oral, and skin-related side effects. Results: Injection site pain (89.8%), fatigue (62.2%), headache (45.6%), muscle pain (37.1%), and chills (33.9%) were the most commonly reported side effects. All the general side effects were more prevalent among the ≤43-year-old group, and their duration was mainly one day (45.1%) or three days (35.8%) following the vaccine. Antihistamines were the most common drugs associated with side effects, thus requiring further investigation. The people with two doses were generally associated with a higher frequency of side effects. Conclusions: The distribution of side effects among Czech healthcare workers was highly consistent with the manufacturer’s data, especially in terms of their association with the younger age group and the second dose. The overall prevalence of some local and systemic side effects was higher than the manufacturer’s report. Further independent studies on vaccine safety are strongly required to strengthen public confidence in the vaccine.

Links

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(CEP code: EF16_013/0001826)
Name: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministry of Education, Youth and Sports of the CR, Priority axis 1: Strengthening capacities for high-quality research
LTC20031, research and development project
Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST
MUNI/A/1608/2020, interní kód MU
Name: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
Investor: Masaryk University
MUNI/IGA/1543/2020, interní kód MU
Name: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Acronym: Evidence-Based Practice in Czechia)
Investor: Masaryk University
90128, large research infrastructures
Name: CZECRIN III